Drugs / RO7566802
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06031441 | Nov 2023 → Dec 2027 expected | cancer, metastatic neoplasm | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7566802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06031441 ↗ |
| Route | Intravenous | “receive escalating doses of RO7566802, as an intravenous (IV) infusion on Day 1 of each 21-day cycle” NCT06031441 ↗ |